The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Open accessAbstract
Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication (ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) have a 1-year survival rate below 20%. We observed that sorafenib, a multitargeted tyrosine kinase inhibitor, increased IL-15 production by FLT3-ITD+ leukemia cells. This synergized with the allogeneic CD8+ T cell response, leading to long-term survival in six mouse models of FLT3-ITD+ AML. Sorafenib-related IL-15 production caused an increase in CD8+CD107a+IFN-γ+ T cells with features of longevity (high levels of Bcl-2 and reduced PD-1 levels), which eradicated leukemia in secondary recipients. Mechanistically, sorafenib reduced expression of the transcription factor ATF4, thereby blocking negative regulation of interferon regulatory factor 7 (IRF7) activation, which enhanced IL-15 transcription. Both IRF7 knockdown and ATF4 overexpression in leukemia cells antagonized sorafenib-induced IL-15 production in vitro. Human FLT3-ITD+ AML cells obtained from sorafenib responders following sorafenib therapy showed increased levels of IL-15, phosphorylated IRF7, and a transcriptionally active IRF7 chromatin state. The mitochondrial spare respiratory capacity and glycolytic capacity of CD8+ T cells increased upon sorafenib treatment in sorafenib responders but not in nonresponders. Our findings indicate that the synergism of T cells and sorafenib is mediated via reduced ATF4 expression, causing activation of the IRF7–IL-15 axis in leukemia cells and thereby leading to metabolic reprogramming of leukemia-reactive T cells in humans. Therefore, sorafenib treatment has the potential to contribute to an immune-mediated cure of FLT3-ITD-mutant AML relapse, an otherwise fatal complication after allo-HCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
A framework for oligonucleotide microarray preprocessing
Carvalho, B. S., & Irizarry, R. A. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq431 · Cited by 1,550
Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development
van der Windt, G. J. W., Everts, B., Chang, C.-H., Curtis, J. D., Freitas, T. C., Amiel, E., Pearce, E. J., & Pearce, E. L. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.007 · Cited by 1,540
Self-citationMitochondrial Dynamics Controls T Cell Fate through Metabolic Programming
Buck, M. D., O’Sullivan, D., Klein Geltink, R. I., Curtis, J. D., Chang, C.-H., Sanin, D. E., Qiu, J., Kretz, O., Braas, D., van der Windt, G. J. W., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.035 · Cited by 1,443
Self-citationGAGE: generally applicable gene set enrichment for pathway analysis
Luo, W., Friedman, M. S., Shedden, K., Hankenson, K. D., & Woolf, P. J. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-161 · Cited by 1,333
Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L. N., Karoly, E. D., Freeman, G. J., Petkova, V., Seth, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms7692 · Cited by 1,202
T cell metabolism drives immunity
Buck, M. D., O’Sullivan, D., & Pearce, E. L. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20151159 · Cited by 1,179
Self-citationBoeva, V., Popova, T., Bleakley, K., Chiche, P., Cappo, J., Schleiermacher, G., Janoueix-Lerosey, I., Delattre, O., & Barillot, E. (2012) · Bioinformatics · doi:10.1093/bioinformatics/btr670 · Cited by 1,007
Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 887
The ConsensusPathDB interaction database: 2013 update
Kamburov, A., Stelzl, U., Lehrach, H., & Herwig, R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1055 · Cited by 807
CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability
van der Windt, G. J. W., O’Sullivan, D., Everts, B., Huang, S. C.-C., Buck, M. D., Curtis, J. D., Chang, C.-H., Smith, A. M., Ai, T., Faubert, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221740110 · Cited by 523
Self-citationGraft-versus-host disease is enhanced by extracellular ATP activating P2X7R
Wilhelm, K., Ganesan, J., Müller, T., Dürr, C., Grimm, M., Beilhack, A., Krempl, C. D., Sorichter, S., Gerlach, U. V., Jüttner, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2242 · Cited by 435
Self-citationRöllig, C., Serve, H., Hüttmann, A., Noppeney, R., Müller-Tidow, C., Krug, U., Baldus, C. D., Brandts, C. H., Kunzmann, V., Einsele, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00362-9 · Cited by 401
Self-citationEx vivo identification, isolation and analysis of tumor-cytolytic T cells
Rubio, V., Stuge, T. B., Singh, N., Betts, M. R., Weber, J. S., Roederer, M., & Lee, P. P. (2003) · Nature Medicine · doi:10.1038/nm942 · Cited by 400
Barnes, B. J., Moore, P. A., & Pitha, P. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101216200 · Cited by 388
Serve, H., Krug, U., Wagner, R., Sauerland, M. C., Heinecke, A., Brunnberg, U., Schaich, M., Ottmann, O., Duyster, J., Wandt, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4990 · Cited by 313
Self-citationSchwab, L., Goroncy, L., Palaniyandi, S., Gautam, S., Triantafyllopoulou, A., Mocsai, A., Reichardt, W., Karlsson, F. J., Radhakrishnan, S. V., Hanke, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3517 · Cited by 302
Self-citationChen, Y.-B., Li, S., Lane, A. A., Connolly, C., Del Rio, C., Valles, B., Curtis, M., Ballen, K., Cutler, C., Dey, B. R., et al. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.09.007 · Cited by 236
Self-citationMetzelder, S. K., Schroeder, T., Finck, A., Scholl, S., Fey, M., Götze, K., Linn, Y. C., Kröger, M., Reiter, A., Salih, H. R., et al. (2012) · Leukemia · doi:10.1038/leu.2012.105 · Cited by 224
Self-citationTarget Antigens Determine Graft-versus-Host Disease Phenotype
Kaplan, D. H., Anderson, B. E., McNiff, J. M., Jain, D., Shlomchik, M. J., & Shlomchik, W. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5467 · Cited by 211
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
Smith, C. C., Lin, K., Stecula, A., Sali, A., & Shah, N. P. (2015) · Leukemia · doi:10.1038/leu.2015.165 · Cited by 202
Brunner, A. M., Li, S., Fathi, A. T., Wadleigh, M., Ho, V. T., Collier, K., Connolly, C., Ballen, K. K., Cutler, C. S., Dey, B. R., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14260 · Cited by 174
Self-citationThiant, S., Yakoub‐Agha, I., Magro, L., Trauet, J., Coiteux, V., Jouet, J. P., Dessaint, J., & Labalette, M. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.13 · Cited by 103
van Bergen, C. A. M., van Luxemburg-Heijs, S. A. P., de Wreede, L. C., Eefting, M., Borne, P. A. V. D., van Balen, P., Heemskerk, M. H. M., Mulder, A., Claas, F. H. J., Navarrete, M. A., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci86175 · Cited by 100
Zorko, N. A., Bernot, K. M., Whitman, S. P., Siebenaler, R. F., Ahmed, E. H., Marcucci, G. G., Yanes, D. A., McConnell, K. K., Mao, C., Kalu, C. M. K., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415067 · Cited by 96
Self-citationRomieu, R., Solis, M., Nardin, A., Goubau, D., Baron‐Bodo, V., Lin, R., Massie, B., Salcedo, M., & Hiscott, J. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1279 · Cited by 91
Antar, A. I., Kharfan‐Dabaja, M. A., Mahfouz, R. A., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.12.005 · Cited by 90
5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft
Lohmeyer, J. K., Bertz, H., Wäsch, R., Marks, R., Zeiser, R., Bogatyreva, L., Finke, J., & Lübbert, M. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.10 · Cited by 83
Self-citationPfirrmann, M., Ehninger, G., Thiede, C., Bornhäuser, M., Krämer, M., Röllig, C., Hasford, J., & Schaich, M. A. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70326-6 · Cited by 80
Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease
Blaser, B. W., Roychowdhury, S., Kim, D. J., Schwind, N. R., Bhatt, D., Yuan, W., Kusewitt, D. F., Ferketich, A. K., Caligiuri, M. A., & Guimond, M. (2004) · Blood · doi:10.1182/blood-2004-05-1687 · Cited by 78
Self-citationThe Role of IL-15 in Activating STAT5 and Fine-Tuning IL-17A Production in CD4 T Lymphocytes
Pandiyan, P., Yang, X., Saravanamuthu, S. S., Zheng, L., Ishihara, S., O’Shea, J. J., & Lenardo, M. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201476 · Cited by 70
Sengsayadeth, S. M., Jagasia, M., Engelhardt, B., Kassim, A. A., Strickland, S. A., Goodman, S. A., Lucid, C., Vnencak‐Jones, C. L., Greer, J. P., & Savani, B. N. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.88 · Cited by 67
Azimi, N., Tagaya, Y., Mariner, J. M., & Waldmann, T. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.16.7338-7348.2000 · Cited by 67
Phosphorylation‐dependent binding of 14‐3‐3 terminates signalling by the Gab2 docking protein
Brummer, T., Larance, M., Abreu, M. T. H., Lyons, R. J., Timpson, P., Emmerich, C. H., Fleuren, E. D. G., Lehrbach, G. M., Schramek, D., Guilhaus, M., et al. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.159 · Cited by 61
Self-citationLiang, Q., Deng, H., Sun, C., Townes, T. M., & Zhu, F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002240 · Cited by 57
van Bockel, D. J., Price, D. A., Munier, C. M. L., Venturi, V., Asher, T. E., Ladell, K., Greenaway, H. Y., Zaunders, J., Douek, D. C., Cooper, D. A., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001807 · Cited by 44
Tschan‐Plessl, A., Halter, J. P., Heim, D. A., Medinger, M., Passweg, J. R., & Gerull, S. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2461-5 · Cited by 38
Self-citationExpression of interleukin 15 in primary adult acute lymphoblastic leukemia
Wu, S., Fischer, L., Gökbuget, N., et al. (2009) · Cancer · doi:10.1002/cncr.24729 · Cited by 36
Chen, G., Wu, D., Wang, Y., Cen, J., Feng, Y., Sun, A., Tang, X., Chang, H., & Zhu, Z. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01108.x · Cited by 27
Sauter, C. T., Bailey, C. P., Panis, M., Biswas, C. S., Budak-Alpdoǧan, T., Durham, A. C., Flomenberg, N., & Alpdoğan, Ö. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.47 · Cited by 14
Nasiłowska‐Adamska, B., Czyż, A., Markiewicz, M., Rzepecki, P., Piątkowska‐Jakubas, B., Paluszewska, M., Dzierżak‐Mietła, M., Solarska, I., Borg, K., Prochorec‐Sobieszek, M., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12575 · Cited by 9
Cited by
The cancer–natural killer cell immunity cycle
Huntington, N. D., Cursons, J., & Rautela, J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0272-z · Cited by 566
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Toffalori, C., Zito, L., Gambacorta, V., Riba, M., Oliveira, G., Bucci, G., Barcella, M., Spinelli, O., Greco, R., Crucitti, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0400-z · Cited by 401
Self-citationImmune escape and immunotherapy of acute myeloid leukemia
Vago, L., & Gojo, I. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129204 · Cited by 341
Self-citationFLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Kiyoi, H., Kawashima, N., & Ishikawa, Y. (2020) · Cancer Science · doi:10.1111/cas.14274 · Cited by 298
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Antar, A. I., Otrock, Z. K., Jabbour, E., Mohty, M., & Bazarbachi, A. (2020) · Leukemia · doi:10.1038/s41375-019-0694-3 · Cited by 243
Metadata
- Authors
- Mathew, N. R., Baumgartner, F., Braun, L., O'Sullivan, D., Thomas, S., Waterhouse, M., Müller, T. A., Hanke, K., Taromi, S., Apostolova, P., Illert, A. L., Melchinger, W., Duquesne, S., Schmitt-Graeff, A., Osswald, L., Yan, K.-L., Weber, A., Tugues, S., Spath, S., Pfeifer, D., Follo, M., Claus, R., Lübbert, M., Rummelt, C., Bertz, H., Wäsch, R., Haag, J., Schmidts, A., Schultheiss, M., Bettinger, D., Thimme, R., Ullrich, E., Tanriver, Y., Vuong, G. L., Arnold, R., Hemmati, P., Wolf, D., Ditschkowski, M., Jilg, C., Wilhelm, K., Leiber, C., Gerull, S., Halter, J., Lengerke, C., Pabst, T., Schroeder, T., Kobbe, G., Rösler, W., Doostkam, S., Meckel, S., Stabla, K., Metzelder, S. K., Halbach, S., Brummer, T., Hu, Z., Dengjel, J., Hackanson, B., Schmid, C., Holtick, U., Scheid, C., Spyridonidis, A., Stölzel, F., Ordemann, R., Müller, L. P., Sicre-de-Fontbrune, F., Ihorst, G., Kuball, J., Ehlert, J. E., Feger, D., Wagner, E.-M., Cahn, J.-Y., Schnell, J., Kuchenbauer, F., Bunjes, D., Chakraverty, R., Richardson, S., Gill, S., Kröger, N., Ayuk, F., Vago, L., Ciceri, F., Müller, A. M., Kondo, T., Teshima, T., Klaeger, S., Kuster, B., Kim, D., Weisdorf, D., van der Velden, W., Dörfel, D., Bethge, W., Hilgendorf, I., Hochhaus, A., Andrieux, G., Börries, M., Busch, H., Magenau, J., Reddy, P., Labopin, M., Antin, J. H., Henden, A. S., Hill, G. R., Kennedy, G. A., Bar, M., Sarma, A., McLornan, D., Mufti, G., Oran, B., Rezvani, K., Shah, O., Negrin, R. S., Nagler, A., Prinz, M., Burchert, A., Neubauer, A., Beelen, D., Mackensen, A., von Bubnoff, N., Herr, W., Becher, B., Socié, G., Caligiuri, M. A., Ruggiero, E., Bonini, C., Häcker, G., Duyster, J., Finke, J., Pearce, E., Blazar, B. R., & Zeiser, R.
- Venue
- Nature Medicine
- Published
- 2018-02-12
- Volume
- 24
- Issue
- 3
- Pages
- 282-291
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2788680157
- Cited by
- 295
- References
- 46
- FWCI
- 19.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.